SCHEMBL4965778

SCHEMBL4965778

NC(CC(=O)O)c1ccc(O)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 10/20 0.54
BLM P54132 6/20 0.54
LMNA P02545 5/20 0.54
ADRA1A P35348 2/20 0.54
PTGS1 P23219 2/20 0.54
NR1I2 O75469 1/20 0.54
KDM4E B2RXH2 9/20 0.50
RECQL P46063 8/20 0.50
MAPT P10636 6/20 0.50
MAPK1 P28482 3/20 0.50
HIF1A Q16665 3/20 0.50
HSD17B10 Q99714 3/20 0.50
PMP22 Q01453 2/20 0.50
TSHR P16473 2/20 0.50
NFKB1 P19838 2/20 0.50
THPO P40225 2/20 0.50
POLB P06746 2/20 0.50
ADRB2 P07550 2/20 0.49
ADRB1 P08588 2/20 0.49
ADRA2A P08913 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8289998 1.00 TDP1 (0.54) TDP1BLMLMNAADRA1APTGS1
SCHEMBL27681258 1.00 TDP1 (0.54) TDP1BLMLMNAADRA1APTGS1
SCHEMBL8766647 0.84 KMT2A (0.43) TDP1BLMLMNAADRA1APTGS1
SCHEMBL13395908 0.84 TDP1 (0.49) TDP1BLMLMNAADRA1APTGS1
SCHEMBL27630117 0.82 KMT2A (0.48) LMNAADRA1APTGS1NR1I2KDM4E
SCHEMBL10381531 0.80 GAA (0.53) TDP1BLMLMNATSHRNFKB1
SCHEMBL5597196 0.80 GAA (0.68) TDP1BLMLMNAPMP22TSHR
SCHEMBL14640249 0.79 TDP1 (0.60) TDP1BLMLMNAADRA1APTGS1
SCHEMBL30420447 0.79 TDP1 (0.60) TDP1BLMLMNAADRA1APTGS1
SCHEMBL11141488 0.79 TDP1 (0.60) TDP1BLMLMNAADRA1APTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0357565-A2 New process for the synthesis of the levodopa MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) 1990-03-07 EP claimed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 CN disclosed
CN-117363548-A Recombinant bacterium for producing phenylpropionic acid and derivatives thereof, construction method and application thereof 杭州唯铂莱生物科技有限公司 2024-01-09 CN disclosed
US-11234975-B2 Levorphanol prodrugs and processes for making and using them KEMPHARM, INC. (US) 2022-02-01 US disclosed
US-11214544-B2 Dextrorphan prodrugs and processes for making and using them KEMPHARM, INC. (US) 2022-01-04 US disclosed
EP-3189840-B1 METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME KEMPHARM INC (US) 2021-05-19 EP disclosed
US-20210002226-A1 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2021-01-07 US disclosed
US-20200390757-A1 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2020-12-17 US disclosed
US-20200392087-A1 DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM ALTER DOMUS (US) LLC 2020-12-17 US disclosed
US-20190142815-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same ALTER DOMUS (US) LLC 2019-05-16 US disclosed
EP-2736510-B1 METHYLPHENIDATE-PRODRUGS, PROCESSES OF MAKING AND USING THE SAME KEMPHARM INC (US) 2017-03-01 EP disclosed
US-20170049765-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same COMMAVE THERAPEUTICS SA (CH) 2017-02-23 US disclosed
US-9453037-B2 Methylphenidate-prodrugs, processes of making and using the same KEMPHARM, INC (US) 2016-09-27 US disclosed
US-20150266911-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same COMMAVE THERAPEUTICS SA (CH) 2015-09-24 US disclosed
US-9079928-B2 Methylphenidate-oxoacid conjugates, processes of making and using the same KEMPHARM, INC. (US) 2015-07-14 US disclosed
US-20140243291-A1 METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME COMMAVE THERAPEUTICS SA (CH) 2014-08-28 US disclosed
US-20100040689-A1 GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS DEPOMED, INC. (US) 2010-02-18 US disclosed
EP-1959948-A2 LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF Xenoport, Inc. (US) 2008-08-27 EP disclosed
WO-2007067495-A2 LEVODOPA PRODRUG MESYLATE, COMPOSITIONS THEREOF, AND USES THEREOF XENOPORT, INC. (US) 2007-06-14 WO disclosed
WO-2005030735-A1 TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390757-A1 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM OPRM1, OPRL1, OPRK1 TDP1 1241/4885BLM 4734/4885LMNA 2822/4885
US-20140243291-A1 METHYLPHENIDATE-OXOACID CONJUGATES, PROCESSES OF MAKING AND USING THE SAME COMT, PNMT, SLC6A3 TDP1 260/4885BLM 3708/4885LMNA 4331/4885
US-20170049765-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same COMT, TPMT, PNMT TDP1 215/4885BLM 3918/4885LMNA 4533/4885
US-20150266911-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same COMT, TPMT, PNMT TDP1 215/4885BLM 3918/4885LMNA 4533/4885
US-11234975-B2 Levorphanol prodrugs and processes for making and using them OPRM1, OPRL1, OPRK1 TDP1 1241/4885BLM 4734/4885LMNA 2822/4885
US-20210002226-A1 LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEM OPRM1, OPRK1, OPRD1 TDP1 1096/4885BLM 4648/4885LMNA 3023/4885
US-20190142815-A1 Methylphenidate-Prodrugs, Processes of Making and Using the Same COMT, TPMT, PNMT TDP1 215/4885BLM 3918/4885LMNA 4533/4885
US-20200392087-A1 DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEM OGFR, OPRM1, CYP4F3 TDP1 4008/4885BLM 4819/4885LMNA 4191/4885
US-11214544-B2 Dextrorphan prodrugs and processes for making and using them OGFR, OPRM1, CYP4F3 TDP1 4008/4885BLM 4819/4885LMNA 4191/4885
US-20100040689-A1 GASTRIC RETENTIVE PHARMACEUTICAL COMPOSITIONS FOR TREATMENT AND PREVENTION OF CNS DISORDERS SLC18A2, SLC18A3, SLC6A2 TDP1 1627/4885BLM 2736/4885LMNA 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.